The contribution of diabetic micro-angiopathy to adverse outcomes in COVID-19

Whyte, Martin B., Vas, Prashanth, Heiss, Christian and Feher, Michael D. (2020) The contribution of diabetic micro-angiopathy to adverse outcomes in COVID-19 Diabetes Research and Clinical Practice, 164, 108217.

Text The contribution of diabetic micro-angiopathy to adverse outcomes in COVID-19.pdf - Accepted version Manuscript Restricted to Repository staff only until 14 May 2021. Download (832kB)

Abstract

Increasing evidence points to endothelial cell dysfunction as a key pathophysiological factor in severe coronavirus disease-19 (COVID-19), manifested by platelet aggregation, microthrombi and altered vasomotor tone. This may be driven by direct endothelial cell entry by the virus, or indirectly by activated inflammatory cascade. Major risk groups identified for adverse outcomes in COVID-19 are diabetes, and those from the Black, Asian and ethnic minority (BAME) populations. Hyperglycaemia (expressed as glycated haemoglobin or mean hospital glucose) correlates with worse outcomes in COVID-19. It is not known whether hyperglycaemia is causative or is a surrogate marker - persistent hyperglycaemia is well known as an aetiological agent in microangiopathy. In this article, we propose that pre-existing endothelial dysfunction of microangiopathy, more commonly evident in diabetes and BAME groups, makes an individual vulnerable to the subsequent ‘endothelitis’ of COVID-19 infection.

Item Type:	Article
Divisions :	Faculty of Health and Medical Sciences > School of Biosciences and Medicine
Authors :	Name Email ORCID Whyte, Martin B. m.b.whyte@surrey.ac.uk Vas, Prashanth Heiss, Christian c.heiss@surrey.ac.uk Feher, Michael D.
Date :	June 2020
DOI :	10.1016/j.diabres.2020.108217
Depositing User :	Clive Harris
Date Deposited :	10 Jun 2020 10:32
Last Modified :	10 Jun 2020 10:32
URI:	http://epubs.surrey.ac.uk/id/eprint/857320

Actions (login required)

View Item

Downloads